CClinicalTrials.gg
CompletedNCT03271463Updated Apr 14, 2021

Assessing Leg Control in People With Chronic Stroke

An observational study in Chronic Stroke, sponsored by University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by University of Minnesota · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years to 79 Years
Sex
All
01

Study summary

The purpose of this study is to compare the clinometric (psychometric) properties of the SCALE and FMA-LE assessments in adults after stroke. A second purpose is to determine how well each measure predicts walking speed using the 10 meter walk test.

Read the detailed description

Selective voluntary motor control may be important in prognosticating future function in adults post stroke. It is therefore important to measure selective voluntary motor control using assessments that are valid, reliable and easy to perform and interpret. Current assessments are time consuming and complicated. Clinicians who work with patients post stroke will benefit from this research because they will have evidence supporting appropriate measurement of selective voluntary motor control. This evidence may inform their clinical decision making when working with patients. Patients who have survived a stroke will benefit because their therapists will be able to better measure their selective voluntary motor control which may one day lead to better prediction of functional outcomes and the selection of appropriate interventions.

The Fugl-Meyer assessment (FMA) is the "Gold Standard" for the assessment of individuals with brain injury, most commonly those surviving cerebrovascular accident (stroke). The full assessment is complicated and can take more than an hour to complete. Clinicians have limited time to perform a full evaluation of their patients, the FMA is just one part of this evaluation. The lower extremity selective voluntary motor control component of the FMA (FMA-LE) is difficult for clinicians who are not experts to perform and interpret. For these reasons, few practicing clinicians use the FMA. However, measuring selective voluntary motor control may be important for prognosticating patients' future functional level and their need for continued therapeutic interventions. The Selective Control Assessment of Lower Extremity (SCALE) was developed for use with children who have cerebral palsy (CP), a condition that in some ways presents similar to stroke. The SCALE has been validated and deemed reliable in the pediatric population with CP. This study aims to determine inter-rater and intra-rater reliability for the FMA-LE and the SCALE. In addition, scores on the SCALE will be compared to scores on the FMA-LE to determine concurrent validity. Finally the scores on the SCALE and FMA-LE will be compared to the time it takes for stroke survivors to walk 10-meters (10-meter walk test) to determine how well each measure predicts functional status (predictive validity).

02

Conditions studied

  • Chronic Stroke

Browse trials for

Keywords

  • stroke
  • selective voluntary motor control
03

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with chronic stroke

Inclusion criteria

  • Adults between 18 and 79 years of age who have sustained a chronic cerebrovascular accident (stroke) with known corticospinal tract damage
  • At least one year after onset
  • Ability to walk
  • Ability to understand and follow simple instructions
  • Written informed consent obtained from subject

Exclusion criteria

Exclusion Criteria:

  • History of cerebellar infarct, traumatic brain injury, tumor, etc.
  • Rigidity, ataxia, or other Cerebellar or Basal Ganglia signs or symptoms.
  • Hospitalizations in the past 6 months.
  • Neurosurgical or Musculoskeletal surgery in last 12 months.
  • Neurological or Musculoskeletal injury within the past month.
  • Pain that interferes with the ability to assume side-lying position.
  • Medication for hypertonicity: Participants may be on medicine for abnormal tone.

However, there must not be any of the following:

  1. Change in dosage or type of medication during the past 6 months
  2. Botox injection(s) within 6 months.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (actual)
Patient registry
No

Groups and cohorts

  • Reliability/Validity of SCALE Assessment

    Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.

    Behavioral: Selective Control Assessment of Lower Extremity (SCALE)

Interventions

  • BehavioralSelective Control Assessment of Lower Extremity (SCALE)

    Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)

05

What researchers measure

Primary outcomes

  1. Selective Control Assessment of Lower Extremity (SCALE)

    Each item is rated 2-0, 2 being Normal and 0 being Unable to Move

    Time frame: Baseline to 4 weeks

Secondary outcomes

  1. Fugl-Meyer Assessment-Lower Extremity component (FMA-LE)

    The complete Fugl-Meyer contains 155 items and each item is rated on a three-point ordinal scale, 2 points for the detail being performed completely, 1 point for the detail being partially completed, and 0 points for the detail not being performed. The maximum score for the motor performance is divided into 66 points for the upper extremity and 34 for the lower extremity. Only the lower extremity motor assessment component of the Fugl-Meyer will be used for this study, which consists of 17 items. Fugl-Meyer Assessment (Upper and lower extremity components). Available from: https://www.researchgate.net/publ

    Time frame: Baseline to 4 weeks

  2. 10-meter walk test

    Performance measure used to assess walking speed in meters per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function. Scoring is done by completing three trials and calculating the average of the three trials to obtain the velocity. The test may be completed at the subject's self-selected velocity and/or at the subject's fast velocity.

    Time frame: Baseline to 4 weeks

06

Study locations

1 site
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
07

References and documents

Publications

  • Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med. 1975;7(1):13-31. PubMed 1135616 ↗

Individual participant data

Plan to share: No — There is not a plan to make IPD available.

08

Registry details

Key details

Study ID
NCT03271463
Lead sponsor
University of Minnesota
Responsible party
Sponsor
First posted
Sep 5, 2017
Start date
Aug 5, 2018
Primary completion
Nov 5, 2020
Completion
Nov 5, 2020
Last update
Apr 14, 2021

Study contacts

Deborah Diaz, PT,PhD
principal investigator · Mary Baldwin University
Teresa A Bisson, PT,DPT,NCS
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion